.Pharmacolibrary.Drugs.V_Various.V09I_TumourDetection.V09IX16_Piflufolastat18f.Piflufolastat18f .Pharmacolibrary.Drugs.V_Various.V09I_TumourDetection.V09IX16_Piflufolastat18f.Piflufolastat18f| name: | Piflufolastat18f |
| ATC code: | V09IX16 | route: | intravenous |
| n-compartments | 2 |
Piflufolastat (18F), also known as 18F-DCFPyL, is a radioactive diagnostic agent indicated for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. It is FDA-approved for use in prostate cancer patients with suspected metastasis or recurrence.
Pharmacokinetic parameters estimated from published clinical characteristics, predominantly in adult male prostate cancer patients, after intravenous administration.